The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The vasomotor menopausal symptoms (VMS) treatment market has experienced robust growth in recent years, surging from $16.6 billion in 2023 to $17.86 billion in 2024, reflecting a compelling Compound Annual Growth Rate (CAGR) of 7.6%. This upward trajectory is propelled by factors such as hormone replacement therapy (HRT), heightened menopause awareness, pharmaceutical advancements, and a surge in consumer demand.

Contributing Factors

• Hormone Replacement Therapy (HRT)
• Menopause Awareness
• Pharmaceutical Developments
• Consumer Demand

Future Outlook: Strong Growth Continues
The VMS treatment market is poised for continued robust growth, with expectations to reach $23.11 billion in 2028, sporting a steady CAGR of 6.7%. Anticipated drivers for this growth in the forecast period include personalized medicine, non-hormonal innovations, nutritional interventions, dietary strategies, and the increasing integration of telemedicine and digital health.

Growth Catalysts

• Personalized Medicine
• Non-hormonal Innovations
• Nutritional and Dietary Interventions
• Telemedicine and Digital Health

Embracing Trends in the Forecast Period
The upcoming years are set to witness major trends shaping the VMS treatment landscape. Natural and alternative approaches, botanical and herbal remedies, menopause support groups, and cognitive behavioral therapy (CBT) are emerging as key trends, reflecting a shift towards holistic and patient-centric approaches.

Noteworthy Trends

• Natural and Alternative Approaches
• Botanical and Herbal Remedies
• Menopause Support Groups
• Cognitive Behavioral Therapy (CBT)

Government Initiatives: Fueling Growth
Government initiatives for women’s health, specifically focusing on menopause, are expected to play a pivotal role in propelling the VMS treatment market forward. Investments in innovative studies, illness prevention programs, and research related to pharmacological, clinical, and epidemiological aspects contribute to a comprehensive approach to women’s health. Notably, the Government of New South Wales allocated $40.3 million over four years to address severe menopausal symptoms, exemplifying the commitment to women’s health.

Government Initiatives

• Funding for Innovative Studies
• Illness Prevention Programs
• Research Related to Pharmacological Aspects
• Comprehensive Women’s Health Initiatives

Industry Leaders Paving the Way
Major players in the VMS treatment market include Pfizer Inc., Abbvie Inc., Novartis AG, and others. These industry giants contribute to the development and innovation in the field, offering a diverse range of treatments to meet the varying needs of women experiencing vasomotor menopausal symptoms.

Key Players

• Pfizer Inc.
• Abbvie Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.

View More On The Vasomotor Menopausal Symptoms (VMS) Treatment Market Report 2023 –  https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

Drug Approvals: Enhancing Treatment Options

To meet the evolving needs of patients, major companies are placing increased emphasis on obtaining drug approvals. Astellas Pharma Inc.’s approval for Veozah in May 2023 is a significant milestone. Veozah, a nonhormonal neurokinin 3 (NK3) receptor antagonist, provides an alternative treatment option for menopausal vasomotor symptoms, offering efficacy and safety benefits compared to existing treatments.

Notable Approval

• Astellas Pharma Inc. receives FDA approval for Veozah
• First nonhormonal NK3 receptor antagonist for menopausal symptoms

Strategic Acquisitions for Market Expansion

Strategic acquisitions are shaping the landscape of the VMS treatment market. In March 2022, Amyris Inc., a biotechnology company, acquired MenoLabs LLC for $35.4 million. This move reflects a broader industry strategy to expand market presence, access new technologies, and cater to a growing customer base in the women’s health sector.

Strategic Acquisition

• Amyris Inc. acquires MenoLabs LLC for $35.4 million
• Expanding women’s health market presence
• Access to new technologies and capabilities

Market Segmentation: Precision in Focus

The VMS treatment market is intricately segmented, offering a detailed understanding of its dynamics. Segments include drug class, distribution channels, and end-users.

Market Segments

1. Drug Class:
   • Antidepressants
   • Hormone Therapy
   • Anticonvulsant
   • Other Drug Classes
2. Distribution Channel:
   • Hospital Pharmacy
   • Retail Pharmacy
   • Online Pharmacy
   • Other Distribution Channels
3. End-User:
   • Hospitals
   • Specialty Clinics
   • Homecare
   • Other End-Users

Regional Dominance: North America Takes the Lead
In 2023, North America emerged as the largest region in the VMS treatment market, underscoring the region’s significant role in steering the industry’s growth. As the market continues to evolve, driven by government initiatives, industry innovations, and a heightened focus on women’s health, it is poised to reshape the landscape of menopausal symptom treatment, offering women more choices and improved care.

Request A Sample Of The Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=13051&type=smp

The Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2023  provides a comprehensive overview on the vasomotor menopausal symptoms (VMS) treatment market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the vasomotor menopausal symptoms (VMS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Postmenopausal Osteoporosis Treatment Global Market Report 2023
Menopausal Hot Flashes Global Market Report 2023
Insulin Drugs Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model